uniQure (QURE) CLO Jeannette Potts Sells $145K of Stock

Jeannette Potts, the Chief Legal Officer at uniQure N.V. (NasdaqGS: QURE), sold 5,237 shares of the company on June 15, 2026. The shares were sold at an average price of $27.67 each, amounting to a total transaction value of $144,907.79. This sale was not part of a pre-planned trading program.

Insider Buying and Selling at uniQure N.V.

On the same day, another insider, Balachandran Madhavan, bought 10,000 shares at $8.49, while also selling 10,000 shares at $27.85 in a planned transaction. Rachelle Suzanne Jacques and Robert Gut also sold shares on June 11, 2026, at a price of $27.06 each.

Other Institutional Activity in uniQure N.V.

Aberdeen Group PLC increased its holdings in uniQure by 1,627,746 shares, ending with 5,306,386 shares valued at about $86.76 million. Meanwhile, Two Sigma Investments, LP grew its stake by 1,224,587 shares, resulting in a total of 2,675,871 shares worth $43.75 million. In contrast, RTW Investments, LP reduced its holdings by 1,125,106 shares, leaving it with 2,586,356 shares valued at $42.29 million.

uniQure N.V. Stock Up 28.7%

Shares of uniQure N.V. traded at approximately $26.99. The company has a market capitalization of $1.70 billion and a forward P/E ratio of -9.55, indicating it is not currently profitable. Its beta stands at 1.001, suggesting average market volatility. The stock's 52-week range is between $8.73 and $71.50, with a 50-day moving average of $22.90 and a 200-day moving average of $27.22. The company's current ratio is 10.40, and its quick ratio is 9.97, while its debt-to-equity ratio is significantly high at 365.37.

Analysts Set New Price Targets

On May 6, 2026, HC Wainwright & Co. maintained its 'buy' rating for uniQure with a price target of $50. Chardan Capital also maintained a 'buy' rating with a target of $37 on April 30, 2026. Goldman Sachs held a 'hold' rating with a $10 target on April 20, 2026. The consensus among 11 analysts is a 'buy' rating, with a mean price target of $39.11.

About uniQure N.V.

uniQure N.V. is a biotechnology company based in Amsterdam, Netherlands, focused on developing treatments for rare and serious diseases. Its flagship product, HEMGENIX, helps patients with hemophilia B by enabling them to produce factor IX, reducing bleeding risks. The company is also advancing AMT-130, a gene therapy for Huntington's disease, and other therapies targeting epilepsy, ALS, and Fabry disease. uniQure collaborates with Apic Bio and CLS Bhering for gene therapy development and commercialization.

Bottom Line

Jeannette Potts' recent share sale is part of the ongoing insider activity at uniQure N.V. Investors closely watch insider transactions for potential insights into company performance. The stock is currently trading within a broad 52-week range, and analysts maintain a generally positive outlook with several 'buy' ratings. As always, these insights are based on past filings and may not reflect current positions.